XPhyto Therapeutics Corp.

Recent News

  • XPhyto Therapeutics Corp.: COVID-19 Rapid Screening Test Prototype Validation

    Vancouver, British Columbia--(Newsfile Corp. - July 6, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce that its exclusive diagnostic partner, 3a-Diagnostics GmbH ("3a"), has confirmed successful function of its novel and proprietary COVID-19 (SARS-CoV-2) RNA probes and...

    2020-07-06 3:05 AM ET
  • XPhyto Engages Knox Communications Inc. for Investor Relations Services

    Vancouver, British Columbia--(Newsfile Corp. - July 1, 2020) -  XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC PINK: XPHYF) ("XPhyto" or the "Company") is pleased to announce that it has entered into an investor relations consulting agreement (the "Agreement") with Knox Communications Inc. ("KCI") to carryout marketing and investor...

    2020-07-01 1:31 AM ET
  • XPhyto Therapeutics Corp.: Infectious Disease Oral Screening Test Advancement

    Vancouver, British Columbia--(Newsfile Corp. - June 15, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), has successfully incorporated peptide biosensors into its oral dissolvable thin film...

    2020-06-15 3:30 AM ET
  • XPhyto's Diagnostic Partners Receive BMBF Grant for Infectious Disease Screening Tests

    Vancouver, British Columbia--(Newsfile Corp. - June 10, 2020) -  XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce that its diagnostic partner, 3a-Diagnostics GmbH ("3a") and their contract research collaborators, have received a €254,200 grant from the German Federal Ministry of...

    2020-06-10 3:30 AM ET
  • RETRANSMISSION: COVID-19 Test and Development Programs Update

    Vancouver, British Columbia--(Newsfile Corp. - March 23, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC PINK: XPHYF) ("XPhyto" or the "Company") is pleased to announce updates to its infectious disease programs, particularly as they relate to the COVID-19 (SARS-CoV-2) pandemic.XPhyto's wholly owned German subsidiary, Vektor Pharma TF...

    2020-03-23 3:02 AM ET
  • XPhyto Announces COVID-19 Test and Development Programs Update

    Vancouver, British Columbia--(Newsfile Corp. - March 20, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC Pink: XPHYF) ("XPhyto" or the "Company") is pleased to announce updates to its infectious disease programs, particularly as they relate to the COVID-19 (SARS-CoV-2) pandemic.XPhyto's wholly owned German subsidiary, Vektor Pharma TF...

    2020-03-20 4:15 PM ET
  • XPhyto Therapeutics Epilepsy Treatment Program

    Vancouver, British Columbia--(Newsfile Corp. - March 19, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) (OTC: XPHYF) ("XPhyto" or the "Company") is pleased to announce significant progress with respect to development of its cannabidiol ("CBD") based Epilepsy product. Further to the Company's press release dated December 9, 2019, titled...

    2020-03-19 12:45 PM ET
  • XPhyto Therapeutics Initiates Infectious Disease Programs

    Vancouver, British Columbia--(Newsfile Corp. - March 3, 2020) - XPhyto Therapeutics Corp. (CSE: XPHY) (FSE: 4XT) ("XPhyto" or the "Company") is pleased to announce that its wholly owned German subsidiary, Vektor Pharma TF GmbH ("Vektor"), will be commencing several research and development programs related to infectious disease. These programs include...

    2020-03-03 4:05 AM ET